What type of study is this?

This is a Literature Review study.

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis, and Treatment

View Full Paper

Ask AI

Bookmark

HRD prevalence ranges from ~50% in high-grade serous ovarian carcinoma to 50–70% in triple-negative breast cancer, impacting therapeutic approaches.
Advanced detection methods integrate genomic and epigenetic profiling, achieving over 90% sensitivity for identifying HRD.
HRD strongly predicts response to PARP inhibitors and platinum therapies, extending progression-free survival by up to 36 months.
Resistance mechanisms and assay variability present challenges, emphasizing the need for standardized diagnostics across populations.

No takes yet. Share an insight, caveat, or question.

Narrative review highlights the role of HRD biomarkers in improving diagnosis and treatment outcomes for ovarian and breast cancers.

Shah et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark